Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib

• Main Authors: Sara Alkhezayem (Author), Tanveer A. Wani (Author), Salma Wakil (Author), Ashwaq Aljuraysi (Author), Seema Zargar (Author)
• Format: Knjiga
• Izdano: Elsevier, 2020-08-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Human estrogen receptor positive cancer cells have mutations and make an excess of the HER2 protein and are far more aggressive than others cancers. Neratinib, an irreversible tyrosine kinase inhibitor is used to treat HER2 positive cancers. Neratinib targets HER2 and blocks its signal transduction...